Internal Medicine

Investigator Andrew T. Chan, MD, MPH, discusses his team's recent findings showing a positive link between primary care providers per capita and community vaccination rates.

Data show ≥60% of eligible faricimab patients with DME could extend treatment to every 4 months, while 95% of ranibizumab implants in wetAMD treatment maintained a six-month schedule.

Experts explain the societal, systemic, and clinical challenges that come with managing skin disease in people of color.

Veeral S. Sheth, MD, MBA, discusses the potential value of complement inhibitors for the at-need patient population.

Our third and final episode on physician burnout traces the path towards a solution and ultimately, reformation in the system as a whole.

The treatment met the pre-specified primary endpoint of significantly less weight gain in the ENLIGHTEN-Early trial.

The treatment was comparable to darbepoetin alfa in treating patients with chronic kidney disease who were not undergoing dialysis.

The monoclonal antibody is designed to reduce the need for red blood cell transfusions to hemolysis among adults with the rare disease.

A randomized trial from the University of Chicago suggests achieving a healthy duration of sleep habitually could reduce energy intake and lead to reductions in body weight.

The recent FDA approval of the oral JAK inhibitor could change the landscape of atopic dermatitis management.

In commemoration of Wear Red Day, here's a breakdown of how US regions differ in cardiovascular disease burden among women.

Comparing SGLT2 inhibitor and GLP-1 RA use versus DPP-4 inhibitors in patients with type 2 diabetes, investigators found use of newer glycemic agents could provide protection against NAFLD in addition to their cardiorenal protective benefits.

New findings observing links between visual acuity, disease progression and risk loci could inform new clinical studies of the leading cause of irreversible vision loss.

Future studies should focus on subgroups of patients with Crohn’s disease treated with ustekinumab.

Monthly IV pegcetacoplan was associated with 39% reduced risk of progression from incomplete to complete RPE and outer retinal atrophy.

Data from the Teen-LABS study demonstrate undergoing bariatric surgery was associated with an increase in testosterone levels among adolescent males with subnormal serum testosterone levels.

New research suggests men with hypersexual disorder had increased plasma oxytocin levels and indicate cognitive-behavioral therapy was associated with a decrease in these levels as well as symptoms of hypersexual disorder.

Our 5 experts return to examine the far-reaching repercussions of the COVID-19 pandemic on the physician burnout crisis.

New data show use exceeding the recommended daily dose for sleep aid has increased nearly 4-fold in the last 15 years.

A new assessment of payer incentives offered through physician organizations suggest the dominating emphasis of quantity over quality in pay.

The majority of drugs in development for IBD target inflammation.

About 30% of patients with ulcerative colitis do not adequately respond to anti-TNF therapy.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

A multitude of promising new investigative therapies are on the horizon for inherited retinal disease.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.